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SUMMARY
Human induced pluripotent stem cells (iPSCs) provide a potentially replenishable source for the production of transfusable platelets.
Here, we describe a method to generate megakaryocytes (MKs) and functional platelets from iPSCs in a scalable manner under serum/
feeder-free conditions. The method also permits the cryopreservation of MK progenitors, enabling a rapid ‘‘surge’’ capacity when large
numbers of platelets are needed. Ultrastructural/morphological analyses show no major differences between iPSC platelets and human
blood platelets.iPSC plateletsform aggregates, lamellipodia, and ﬁlopodia afteractivationand circulate in macrophage-depleted animals
and incorporate into developing mouse thrombi in a manner identical to human platelets. By knocking out the b2-microglobulin gene,
we have generated platelets that are negative for the major histocompatibility antigens. The scalable generation of HLA-ABC-negative
platelets from a renewable cell source represents an important step toward generating universal platelets for transfusion as well as a po-
tential strategy for the management of platelet refractoriness.
INTRODUCTION
The vital processes of blood coagulation, clot formation,
and hemostasis rely upon a sufﬁcient supply of platelets
within a person’s bloodstream. Transfusion remains the
most effective way to increase a patient’s blood platelet
count, yet limitations in the supply of platelets is a con-
stant problem. A limited shelf-life (5 days) and the require-
ment for room-temperature storage increase the risk of
bacterial contamination and pose the biggest challenge
for maintaining ample supplies. In addition, patients
who receive multiple platelet transfusions, such as those
with various types of cancer, often develop platelet refrac-
toriness duetoHLAalloreactivity andsubsequently require
additional transfusions with HLA-matched donor platelets
(Schiffer, 2001). Finding alternative sources of nonimmu-
nogenic, high-quality platelets can help alleviate chronic
shortages in the supply of platelets and reduce the risks
for refractoriness.
Generating functional platelets in vitro has been the
focus of many studies (Reems et al., 2010), yet many unre-
solved problems still exist. Human CD34
+ cells from bone
marrow (BM) and umbilical cord blood (CB) are capable
of producing megakaryocytes (MKs) and platelets (Choi
et al., 1995; Matsunaga et al., 2006), but production is
donor dependent and the expansion capability of these
cells is limited. Human embryonic stem cells (hESCs) and
induced pluripotent stem cells (iPSCs) have also been
used to derive both MKs and platelets using different
methods (Lu et al., 2011; Pick et al., 2013; Takayama
et al., 2008, 2010), all of which rely on mouse embryonic
ﬁbroblast (MEF) feeders and serum at some point during
their culture. Since both MEF and serum can potentially
be contaminated with xenogenic pathogens, their use in-
creases the risk for an immunogenic reaction in humans.
‘‘Feeder-free’’ substitutes for MEF, including Matrigel
(BD), CELLstart (Life Technologies), recombinant proteins
(Rodin et al., 2010), and synthetic polymers (Mei et al.,
2010), can be used in the maintenance and propagation
of human pluripotent stem cells (hPSCs). However, the
propensity of feeder-free hPSCs to undergo massive cell
death upon EB formation (Lu et al., 2013) (unpublished
data) greatly reduces their differentiation potential into
all cell lineages. Lastly, retroviral infection with three genes
convertedhuman dermalﬁbroblasts (Onoetal.,2012) cells
to MK-like cells without reprogramming to a pluripotent
state, and these MK-like cells were found to generate
platelet-likeparticlesonlywheninjectedintoimmunodeﬁ-
cient mice (Ono et al., 2012). The use of viral vectors and
the inability to produce platelets from the MK-like cells
in vitro limit the clinical applicability of this approach.
Methods described above all fall short of providing scalable
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ering that one transfusion unit contains approximately
300–600 3 10
9 platelets, the efﬁciency of in vitro methods
will need to be greatly improved if they are to be used
clinically.
The objective of our current investigation is to develop
a clinically adaptable method for large-scale production
of iPSC-MKs and platelets under completely serum- and
feeder-free conditions in vitro. Here, we describe a well-
deﬁned, three-step protocol to differentiate human iPSCs
into MKs and functional platelets in less than 20 days.
Importantly, this method does not utilize serum and ani-
malfeedersatanystageofdifferentiation,whichgreatlyin-
creases its ability to be developed forclinical use. Usingthis
method, large quantities of cryopreservable MK progeni-
tors were produced from human iPSCs, thereby allowing
billions of platelets to be produced rapidly upon thawing
of these cells. The improved scale of platelet generation
provided enough material to perform light transmission
aggregometry (LTA) of fully in vitro-generated platelets, as
wellasotherimportantfunctionalassaysincludingplatelet
circulation kinetics in living animals. In addition, by
knocking out the b2 microglobulin gene in iPSCs, we ge-
nerated HLA major (A,B,C)-negative MKs and platelets.
This can facilitate future clinical development of a renew-
able ‘‘universal’’ platelet source to help reduce the inci-
dence of refractoriness in vulnerable patient populations.
RESULTS
Efﬁcient Serum- and Feeder-free Direct Differentiation
ofHumaniPSCstoCD31
+HemogenicEndothelial-like
Cells and MK Progenitors
Feeder-freeiPSCsweredifferentiatedintohemogenicendo-
thelial-like cells and hematopoietic progenitor intermedi-
ates prior to further differentiation into MKs and platelets
(Figures 1A and 1B). In the ﬁrst 6 days of differentiation,
we observed dramatic morphological changes: compact
colonies (day 0) stretched out and became loose colonies
(day 3), which grew out and formed sheets with a complex
morphology by day 6 (Figure 1C). Cell-surface marker anal-
ysis on day 6 showed that 58.5% (±3.74%) of attached cells
were CD31
+. Approximately 34.43% of these cells were
CD34
+ and less than 10% of them were CD43
+, indicating
an early stage of hematopoietic commitment (Vodyanik
et al., 2006). Further analyses demonstrated that between
30% and 60% of the attached cells also expressed CD144
(vascular-endothelial [VE] cadherin), CD105, CXCR4, and
KDR (Figure 1D). As CD31 (PECAM-1) has been shown to
be an important marker for hemogenic endothelium
(Oberlinetal.,2002),wefurtherdeterminedtheexpression
of several surface markers that are also expressed on hemo-
genic endothelium on both our CD31
+ and CD31
  cells.
Flow cytometry analyses demonstrated that about 67.5%
and 63.1% of CD31
+ cells expressed CD105 and VE
cadherin, respectively, whereas only about 10.9% and
5.8% of CD31
  cells were positive for CD105 and VE cad-
herin (Figure 1E). Hematopoietic colony-forming assays
showed that CD31
+ cells possess robust hematopoietic
potential with the development of colony-forming unit
(CFU)-erythroid, CFU-myeloid, and CFU-mixture, whereas
CD31
  cells developed very limited numbers of hemato-
poietic colonies (Figure 1F; Figure S1 available online).
After plating on a ﬁbronectin-coated surface, CD31
+ cells
formed a monolayer with characteristics of endothelium
morphology, expressed high levels of von Willebrand fac-
tor (vWF), and took up acetylated low-density lipoprotein
(LDL) (Figure 1G). These results demonstrate that CD31
+
hemogenic endothelial-like cells can be efﬁciently gener-
ated by direct differentiation of feeder-free iPSCs under
deﬁned conditions.
Six days after initial differentiation, culture medium was
replaced by expansion medium EXP-M. From day 6 + 1 to
day 6 + 4, large numbers of rounded cells grew out of the
attached cells as shown in Figure 1C. The majority of these
ﬂoating cells were CD31
+CD34
+CD43
+, indicating their
commitment toward the hematopoietic lineage (Vodyanik
et al., 2006). These ﬂoating cells were also CD41a
+
CD13
+CD14
 , and expression of the MK-speciﬁc marker
CD42b was variable (9.5%–37%). We therefore deﬁned
these cells as megakaryocyte progenitors (MKPs) by cell-
surface marker expression (CD31
+CD34
+CD43
+CD41a
+
CD13
+CD14
 CD42b
+/ )( Figure S2). However, we also
observed that CD14
+ myeloid cells (which are almost
100% CD42b
 ) increased from <1% to about 38% from
day 6 + 1 to day 6 + 7, indicating the expansion rate of
myeloid cells surpassed that of MKPs during this time
period (Figures 2A and 2B). In ﬁve large-scale experiments,
we generated a total of 2.06 3 10
9 MKPs from 1.26 3 10
8
iPSCs, an average of >16 MKPs per single iPSC input
(Table S1).
Downregulation of myc Promotes MKP Formation
and Prohibits Myeloid Cell Expansion
Previous studies suggest that the c-myc gene may be
involved in megakaryopoiesis (Chanprasert et al., 2006;
Guo et al., 2009; Thompson et al., 1996). We therefore
determined whether suppression of c-myc expression
would enhance MK lineage differentiation/expansion and
simultaneously prohibit myeloid and other lineage differ-
entiation/expansion. MKP day 6 + 3 cultures were treated
with noncytotoxic doses of a c-myc inhibitor, iBET151
(0.1 and 0.25 mM), for 24 hr and then harvested for anal-
ysis. Quantitative PCR analyses showed a dose-dependent
downregulation of myc and upregulation of gata1 in
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Generation of Universal Platelets from Human iPSCsMKPs treated with iBET151 (Figure 2C). Supplementation
of iBET151 at 0.1 and 0.25 mM resulted in  2- and 4-fold
increases in MKP outputs, respectively, as compared to un-
treated controls (Figure 2D). Results also showed that addi-
tion of iBET151 from day 6+3t od a y6+4inhibited the
formation of CD14
+ myeloid cells in a dose-dependent
manner (Figure 2E). CD14
+ myeloid cells were decreased
from about 12% in control cultures to less than 5% and
3% in cultures treated with iBET151 at 0.1 and 0.25 mM,
respectively. These results suggest that the c-myc gene not
only plays a key role in early megakaryopoiesis, which is
consistent with previous reports (Takayama et al., 2010),
but also may be involved in the differentiation and expan-
sion of other hematopoietic lineages.
Feeder-free Generation of Platelets from iPSC MKs
We previously found that 40%–50% CD41a
+/CD42b
+ dou-
ble-positive platelets were generated from MKs with
stroma/feeder coculture whereas this amount decreased
to <15% when feeder-free conditions were used (Lu
et al., 2011). To overcome the requirement for feeders
and improve production of CD41a/CD42b double-
positive MKs and platelets, we tested several conditions
with different basal media and cytokine/growth factor
Figure 1. Generation of Megakaryocyte Progenitors from Human iPSCs
(A) Schematic illustration of step-wise differentiation from iPSCs to MKPs.
(B) Schematic illustration of iPSC MK maturation and platelet production.
(C) Representative cell morphology at various stages of MK lineage speciﬁc differentiation (scale bar, 100 mm).
(D) Cell-surface marker analyses of day 6 differentiation culture (mean ± SD, n = 3).
(E) Representative ﬂow cytometry proﬁles of cell-surface markers in day 6 CD31
+ (upper panel) and CD31
  (lower panel) cells (black line,
isotype antibody control; red line, speciﬁc antibody).
(F) Colony-forming capability of day6 CD31
+ and CD31
  cells (mean ± SD, n = 3).
(G) From left to right: Morphology of endothelial cells derived from day 6 CD31
+ cells; uptake of LDL (red) and staining of CD31 (green);
uptake of LDL (red) and vWF staining (green) (scale bar, 20 mm).
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Generation of Universal Platelets from Human iPSCscombinations. Our results showed that a combination of
STEMspan-ACF medium with STEMspan Megakaryocyte
Expansion Supplement (STEMCELL Technologies) as the
core components of MK maturation medium was the best
mediumandcytokinemixturetestedforiPSCMKPmatura-
tion and subsequent platelet production. As shown in
Figure 2. Effect of the myc-Inhibitor iBET on Differentiation of MKPs to Mature MKs
(A) Representative results showing percentage of CD41a
+CD42b
+ and CD14
+ MKPs from day 6 + 1 to day 6 + 4.
(B) Time-dependent change of CD41a
+CD42b
+ and CD14
+ MKPs percentage from day 6 + 1 to day 6 + 7 (mean ± SD, n = 3).
(C) Dose-dependent effect of iBET on MYC and GATA1 mRNA expression in MKPs (mean ± SD, n = 3).
(D) Dose-dependent effect of iBET on MKP yield (mean ± SD, n = 3).
(E) Dose-dependent inhibitory effect of iBET on CD14
+ cells in MKP culture (mean ± SD, n = 3).
(F) Representative results of CD42b and CD235a expression in MKPs and mature MKs (MMK).
(G) Comparative expression of CD42b and CD235a in MKPs and MMKs (mean ± SD, n = 3).
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Generation of Universal Platelets from Human iPSCsFigures 2F and 2G, culturing of MKPs in this medium for
4 days resulted in a rapid increase in the CD41a
+CD42b
+
double-positive matured MK population from  20% to
>80% and the almost complete elimination of CD235A
+
erythroid cells. These results indicate that this MK matura-
tion medium efﬁciently steers cells toward MK lineage
developmentwhilesuppressingtheexpansionoferythroid
cellseventhoughthesecelltypesshareacommonbipoten-
tial progenitor (Klimchenko et al., 2009).
Although results vary among different cell lines, large
MKs (black arrow) and distinctive proplatelet structures
(red arrows) were present in 3–4 days of MK cultures (Fig-
ure 3A). No difference was observed between MKs derived
fromiPSCandhESCsinformingproplatelets.Todetermine
if proplatelets in the cultures (Figure 3A) reﬂect the genera-
tion of platelets, we examined CD41a/CD42b expression
oniPSCplateletspuriﬁedbyBSAgradientsegregation(Rob-
ert et al., 2012). Using human blood platelets to establish
proper size gating (Figure 3B, left panels), we observed
that more than 70% of both iPSC and hESC platelets gener-
ated under feeder- and serum-free conditions expressed
both CD41a and CD42b, which is similar to human blood
platelets (82%). To our knowledge, this is the ﬁrst time
that platelets with such high purity have been generated
Figure 3. Generation of Platelets from Human iPSC-Derived MKs
(A) Morphology of hiPSC- and hESC-derived proplatelets (red arrows), large MKs (black arrows), and small MKs (white arrows).
(B) Flow cytometry proﬁle of human circulating platelets, hESC platelets, and iPSC platelets and the percentage of CD41a
+CD42b
+ platelets
within identical gate (P1).
(C) Time-dependent variability of platelet generating capability of MKPs (mean ± SD, n = 3).
(D) Time-dependent change of platelet purity during production peak (mean ± SD, n = 3).
(E) Time-dependent change of platelet overall yield during production peak (mean ± SD, n = 3).
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serum. We found that the quality of platelets (CD41a
+/
CD42b
+ expression) generated from iPSC MKs was in-
versely correlated with the percentage of CD14
+ myeloid
cells in the starting MK cultures, indicating that a pure
MK population is critical for the generation of functional
platelets in vitro. The kinetics of platelet production was
also monitored, and both the purity and quantity of plate-
lets in culture increased gradually from day 4 and peaked at
day 6 (Figures 3C–3E).
Proteases such as MMPs are known to be involved in
shedding of CD42b (GPIba), which is the receptor for
vWF and mediates initial platelet reactions to wounds.
Loss ofCD42b isclosely associatedwith a declineinplatelet
quality.Abroad-spectrumMMPinhibitor,GM6001(GM),is
reported to inhibit CD42b shedding from platelets (Nishikii
et al., 2008; Robert et al., 2011). Consistent with our previ-
ousstudy(Luetal.,2011),theadditionofGMinMKculture
protectedCD42bonplateletsfromsheddingandresultedin
an increase of CD41b
+/CD42b
+ platelets from 45% to 59%
(Figure S3A). However, ﬂow cytometry of GM-treated plate-
lets showed a less homogeneous proﬁle. In a systemic
comparative study using several speciﬁc MMP inhibitors
(unpublished data), we identiﬁed an MMP8-speciﬁc inhibi-
tor (MMP8-I) with superior shedding protection than GM.
Addition of an MMP8-I (20 mM) increased the percentage
of CD41a
+CD42b
+ platelets from  45% to 65%. More
importantly, MMP8-I-treated platelets displayed a more ho-
mogeneous ﬂow cytometry proﬁle (Figure S3A). The total
number of CD41a
+CD42b
+ platelets obtained from MMP8-
I-treated culture ( 74% increase versus control) was also
higher than that from GM-treated cultures ( 46% increase
versuscontrol;FigureS3B),However,nosigniﬁcantsynergis-
tic effect was observed when combining MMP8-I and GM.
Previous studies have suggested that mild hyperthermia
(39 C instead of 37 C) improves MK differentiation/matu-
ration and platelet generation from umbilical cord blood
CD34
+ cells (Pineault et al., 2008; Proulx et al., 2004). How-
ever, it is unclear whether mild hyperthermia will be bene-
ﬁcial to iPSC-derived MK differentiation/maturation and
platelet production. Using the above-described method,
we found that mild hyperthermia (39 C) improved both
the purity (percentage of CD41a
+/CD42b
+; Figure S4A)
and the yield of platelets from iPSC MKs (Figure S3C) dur-
ing the peak platelet production from day 4 to 7 of MK
cultures.
Ultrastructural and Functional Characterization
of iPSC Platelets In Vitro
Thin section electron micrography showed that iPSC plate-
lets were ultrastructurally similar to circulating human
platelets (Figures 4A and 4B). The iPSC platelets have a
discoid shape, display a smooth contour and contain a
normal distribution of the open canalicular system as well
as a- and dense granules and other organelles, which are
indistinguishable from features of human blood platelets
(Figures 4A and 4B). Immunoﬂuorescence micrographs
showed that iPSC platelets were anucleate but, on average,
slightly larger than circulating human blood platelets (2.38
± 0.85 mm versus 2.27 ± 0.49 mm, n > 100) (Figure 4E). How-
ever,sizedistributionofiPSCplateletswassimilartohuman
blood platelets, and these platelets have both normal
tubulincytoskeletonandﬁlamentousactinrelativetocircu-
lating human platelets (Figure 4E) and strongly express
thrombospondin4andplateletfactor4(a-granulemarkers)
(Figures 4F and 4G). In summary, similar to hESC platelets
generated with stromal cells (Lu et al., 2011), iPSC platelets
displayed all of the ultrastructural and morphological
criteria that are characteristic of blood platelets.
TodeterminewhetheriPSCplateletsgeneratedunderthis
stroma-free condition can be activated, we performed a
binding assay using the PAC-1 monoclonal antibody,
which only binds to the activated conformation of aIIbb3
integrin. In response to thrombin treatment, iPSC platelets
showed approximately a 6-fold increase in PAC-1 binding
as compared to resting controls (Figures 5A and 7C), which
is similar to hESC platelets produced with stromal cells but
weaker than human blood platelets as reported previously
(Luetal.,2011;Takayamaetal.,2008).Live-cellmicroscopy
revealed that iPSC platelets spread on a glass surface and
formed lamellipodia and ﬁlopodia with membrane rufﬂing
after stimulation; they also spread out and tethered to each
other, mimicking the early stage of aggregation, which are
characteristics typically observed in blood platelets in
response to activation stimulation (Figure 5B; Movie S1).
LTA is the most common method used in clinical and
research laboratories to assess platelet function (Panzer
andJilma,2011).LTAhasneverbeenperformed withplate-
lets generated from human PSCs in vitro, presumably due
to its requirement for a large quantity of fresh platelets.
As shown in Figure 5C, human peripheral blood (PB) plate-
lets (2.5 3 10
7) resuspended in human plasma reached
 80% aggregation 6 min after exposed to 1 U/ml throm-
bin. Similar numbers of iPSC platelets responded to
1 U/ml of thrombin in forming aggregates, but the process
was slower and aggregation was weaker as compared to PB
platelets: only <30% of aggregation was observed 6 min af-
ter thrombin stimulation. Human CB platelets similarly
showed weak aggregation ( 10%) under the same condi-
tions (Figure 5C), which is consistent with previous obser-
vations that CB platelets showed a weaker aggregation
compared to PB platelets in the LTA assay (Israels, 2013; Is-
raels and Rand, 2013; Israels et al., 2003). Similar results
were observed after exposure of PB and CB platelets and
iPSC platelets to 20 mM ADP (Figure S4), the most common
agonist used for platelet aggregation studies. However, our
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+
cell-derived platelets, which showed no aggregation at all
by LTA (Robert et al., 2011).
iPSC Platelets Generated under Completely Serum-
and Feeder-free Conditions Are Functional In Vivo
Previous studies demonstrated that mouse macrophages
play a major role in rejecting human platelets (Hu and
Yang, 2012). To investigate the kinetics and in vivo func-
tionality of iPSC platelets, nonobese diabetic/severe com-
bined immunodeﬁciency (NOD/SCID) mice were treated
without or with liposome-encapsulated clodronate as
described previously (Hu and Yang, 2012), and 1.5 3 10
7
and 5 3 10
8 blood human platelets were intravenously
infused into these animals. Mouse blood samples were
collected at different time points and analyzed by ﬂow
cytometry with antibodies speciﬁcally against human
CD41and CD42 antigens. We observed that human
Figure 4. Characterization of iPSC-Derived Platelets In Vitro
(A and B) Thin section electron micrographs of (A) human blood and (B) iPSC platelets (AG, a-granules; DTS, dense tubular system; GG,
glycogen granules; M, microtubules; MB, multivesicular body; Mt, mitochondria; OCS, open canalicular systems).
(C) Immunoﬂuorescence micrograph of human whole blood (left) and iPSC platelets (right). Platelets were probed for Hoechst (nuclear
stain, blue), b1-tubulin (microtubule cytoskeleton, green), and phalloidin (ﬁlamentous actin, red).
(D) Inset (iPSC platelet tubulin) shows representative line function for highlighted platelet.
(E) Size distribution of human whole-blood (gray) and iPSC (black) platelets. Platelet diameter was measured in b1-tubulin-labeled cells
for more than 100 individual platelets.
(F) Granule composition of human whole-blood platelets.
(G) Granule composition of iPSC platelets. Platelets were probed for serotonin (dense granule marker), thrombospondin 4, and platelet
factor 4 (a-granule markers).
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Generation of Universal Platelets from Human iPSCsplatelets were removed within 10 min from the circulation
ofliposome-treatedcontrolmice(evenwiththeinfusionof
5 3 10
8 human platelets), whereas human platelets
circulated for at least 8 hr in macrophage-depleted mice
(Figure S5). Therefore, NOD/SCID mice were pretreated
with liposome-encapsulated clodronate to deplete macro-
phages, 1.5 3 10
7 iPSC platelets/mouse were infused intra-
venously, and mouse blood samples were analyzed for hu-
man platelets at different times. Human iPSC platelets,
like human blood platelets, circulated for at least 8 hr in
macrophage-depletedNOD/SCIDmicewithatimetoreach
maximal accumulation (Tmax) of 0.5–1 hr (Figures 6A and
6B); however, no circulating human blood platelets or iPSC
platelets were detected 24 hr after infusion (Figure S6).
Figure 5. Functional Characterization of
iPSC Platelets In Vitro
(A) PAC-1 activation of iPSC platelets by
thrombin.
(B) Time-lapse movie of iPSC platelet
spreading upon activation on glass.
(C) Aggregation assay of platelets from
human peripheral blood (PB), umbilical
cord blood (CB), and iPSC platelets stimu-
lated with 1 U of thrombin using Chronolog
aggregometer.
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Generation of Universal Platelets from Human iPSCsWe previously reported that hESC platelets, like human
blood platelets, incorporated into the developing mouse
thrombus at the site of laser-induced arteriolar injury in
live mice (Lu et al., 2011). To investigate whether iPSC
platelets are functional in vivo, similar experiments were
performed in macrophage-depleted NOD/SCID mice. Like
human blood platelets and hESC platelets, iPSC platelets
incorporated into the growing platelet thrombus with an
average number of 9.0 ± 1.8 platelets per thrombus (Figures
6C and 6D; Movie S2), which was indistinguishable from
human blood platelets. Infusion of human blood platelets
or iPSC platelets did not alter the kinetics of mouse platelet
thrombus formation at the site of arteriolar injury (Tmax =
85–105 s). To examine whether the incorporation of iPSC
platelets into the developing thrombus is mediated by
aIIbb3 integrin, ReoPro (100 mg), a speciﬁc inhibitor of
human aIIbb3 integrin, was infused into the same mouse
treated with human platelets or iPSC platelets. Treatment
with ReoPro markedly abolished human platelet or iPSC
plateletbindingtothegrowingthrombusattheinjurysites
(Figures 6C and 6D; Movie S3), whereas ReoPro did not
affect the number of circulating iPSC platelets or the
Figure 6. Functional Characterization of iPSC Platelets In Vivo
(A) Representative ﬂow cytometry results of iPSC platelet kinetics in macrophage-depleted NOD-SCID mice.
(B) Comparative kinetics of human blood platelets and iPSC platelets (mean ± SD, n = 5).
(C) In vivo thrombus formation of human blood platelets and iPSC platelets.
(D) Quantitative results of in vivo thrombus formation of human whole blood platelets and iPSC platelets (mean ± SEM, n = 6, **p < 0.01);
results are from six injuries of three animals.
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These results suggest that iPSC platelets, like human blood
platelets and hESC platelets, are functional in vivo.
Generation of HLA Major-Negative MKs and Platelets
from b2M
ko iPSCs
MKs and platelets were generated from b2M
ko iPSCs, and
the expression of both b2M and HLA-ABC was measured
with ﬂow cytometry in comparison to those generated
from parental HA-iPSCs. The b2M
ko iPSCs displayed a
normal MK lineage-speciﬁc differentiation capability,
same as their parental HA-iPSCs. MKs derived from HA-
iPSCs, as expected, expressed both b2M and HLA-ABC,
while the expression of both antigens in b2M
ko iPSC MKs
was undetectable (Figure 7A). Similarly, ﬂow cytometry an-
alyses conﬁrmedthat platelets generated from b2M
ko iPSCs
did not express HLA-ABC, whereas platelets derived from
parental iPSCs were HLA-ABC positive (Figure 7B). Both
HLA-ABC-positive and HLA-ABC-negative platelets pos-
sessed similar activation capacity as shown by PAC-1 bind-
ing activity after thrombin treatment (47.1% versus 53.8%;
Figure 7C).
DISCUSSION
Here, we describe a completely feeder-free, serum-free, and
animal component-free system for the derivation of MKs
and platelets from human PSCs, thus rendering the current
system amenable to the development of an in vitro current
good manufacturing practice-compliant platelet manu-
facturing protocol. In particular, our use of a hemogenic
endothelium intermediate instead of embryoid bodies
(EBs) helped avoid inefﬁciencies and inconsistencies with
differentiation of feeder-free PSCs and improved the yield
ofMK progenitors over other methods. The large-scale gen-
eration of pure iPSC platelets allowed us to perform LTA on
platelets derived from PSCs. Roughly 4 billion highly puri-
ﬁed iPSC platelets were derived using this protocol, and
they displayed comparable morphological and functional
properties to human blood platelets when tested in a vari-
etyofinvitroassays andanintravital/laser-induced throm-
bosis model in mice.
The formation of EBs and coculture with stroma such as
OP9cellsarethetwomostcommonlyusedmethodsfordif-
ferentiation of PSCs into a variety of lineages (Choi et al.,
2011; Kennedy et al., 2012; Lu et al., 2007; Takayama
et al., 2008). Yet, data suggest that when using EBs, line-
age-speciﬁc differentiation of feeder-free stem cells is often
compromised by signiﬁcant cell death (Lu et al., 2013) (un-
published data), possibly due to anoikis induced by detach-
ment from the extracellular matrix (ECM). To circumvent
the need for EB formation, collagen IV has been used as
an ECM to support the differentiation of mouse, non-
human primate, and human pluripotent stem cell differen-
tiationtowardmesodermlineages(Gerecht-Niretal.,2003;
Nishikawa et al., 1998; Sone et al., 2003). One study by
Salvagiotto et al. combined the use of collagen IV with a
serum-free medium for early hematopoietic differentiation
offeeder-freePSCsandfoundthattheresultingprogenitors
Figure 7. Generation and Characterization of Universal Platelets from Human iPSCs
(A) HLA-ABC and b2M expression in wild-type HA-iPSCs and b2M
KO iPSC-derived MKs.
(B) HLA-ABC and b2M expression in wild-type HA-iPSCs and b2M
KO iPSC-derived platelets.
(C) Platelet activation measured by PAC-1 binding with (red histogram) or without thrombin (black histogram) in wild-type HA-iPSC
platelets and b2M
KO iPSC platelets.
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(Salvagiotto et al., 2011). However, the propensity of these
MK progenitors to further differentiate into mature, func-
tional platelets was not examined in any detail (Salvagiotto
et al., 2011). We reasoned that if collagen IV could be used
in lieu of EBs to support initial differentiation of feeder-free
PSCs, its use could thus be incorporated into a full-ﬂedged
protocol for the generation of functional platelets. Indeed,
we found that 6 days of growth on collagen IV allowed a
populationofCD31
+hemogenic progenitorswith hemato-
poietic potential to emerge from the starting iPSCs. These
CD31
+ cells could then be efﬁciently differentiated into
MK progenitors, consistently generating  16 MK progeni-
tors from every 1 iPSC. This is a signiﬁcant improvement
over previously reported methods and allowed us to pro-
duce billions of MK progenitors in conventional culture
vessels.
Subsequent differentiation of stem cell-derived MK
progenitors into mature MKs and ultimately platelets
has been notoriously difﬁcult. Coculture with OP9 or
C3H10T1/2 stroma cells has been found to greatly facilitate
the process (Lu et al., 2011; Takayama et al., 2008), but it is
still far from being efﬁcient. We found that optimizing the
combination of medium and cytokines at each unique
phase of MK lineage-speciﬁc differentiation and maturation
together with the use of ultralow-attachment plates can
overcomethenecessityforstroma/MKcoculturetogenerate
high-quality, functional platelets. Indeed, we produced
more pure platelets under this feeder-free system than those
of previous studies using feeder cells (Lu et al., 2011;
Takayama et al., 2008), suggesting that under the right cir-
cumstances, feeder cells are entirely dispensable for platelet
formationinvitro.Ourresultsalsohighlighttheimportance
of media and matrix optimization for future investigation.
Despite these improvements, the current output of
approximately six platelets per MKP is still quite low
compared to platelet output in adult BM, where a mature
MK is capable of producing 2,000–10,000 platelets (Kauf-
man et al., 1965; Long, 1998). This may be due to the inad-
equacy of static in vitro culture conditions and/or the lack
of a pro-MK niche mimicking the BM sinusoid (Junt et al.,
2007). Using microﬂuidic chips, we have recently demon-
strated that approximately 30 platelets per iPSC MK were
generated in vitro under sheer force (Thon et al., 2014), a
5-fold increase in efﬁciency compared to the static condi-
tion used in current study. Although this progress is signif-
icant, the efﬁciency is still very low compared to >2,000
platelets/MK in BM. Currently, it remains the biggest chal-
lenge for reaching a clinically relevant scale of ex vivo
platelets. One strategy for getting around this problem in-
volves the generation of immortalized megakaryocyte pro-
genitor cell lines (imMKCLs) from hematopoietic progeni-
tors with virally transduced genes. These imMKCLs can be
expanded and are capable of producing platelets upon in-
hibition of c-myc, bmi1, and bcl-xL expression (Nakamura
et al., 2014). Although methods involving viral transduc-
tion may not be considered appropriate for clinical-grade
manufacturing, this new study offers insight into mecha-
nisms behind megakaryopoiesis that may help develop
clinically compliant protocols. We found that the efﬁ-
ciency of MK progenitor generation and subsequent
platelet production can be enhanced by transient inhibi-
tion of c-myc expression. Our data indicate that c-myc inhi-
bition using the small molecule iBET151 leads to increased
expression of the erythroid/MK lineage-speciﬁc transcrip-
tion factor GATA-1 and a concomitant decrease in the
production of CD14
+ myeloid cells, both of which likely
enhance MK differentiation and lead to increased platelet
production.Theseobservationsareinlinewithpreviousre-
ports showing that timely alterations in c-myc levels
achieved by inducible c-myc systems (Takayama et al.,
2010; Thompson et al., 1996) or completely knocking out
c-myc expression (Guo et al., 2009) can affect erythroid/
MK lineage commitment, megakaryopoiesis, polyploidy,
and platelet output. As iBET151 is slightly cytotoxic,
more work will need to be done to optimize the concentra-
tion and timing of its use for maximal beneﬁt.
Finally,weprovidedproofofconceptthatourfeeder-free,
serum-free,andanimal-componentfreesystemcanbeused
to generate HLA-ABC
neg, universal platelets by using
TALEN-mediated targeting disruption of the b2-microglo-
bingeneiniPSCs.Knocking outb2M expressioneliminates
HLA class I cell-surface expression (D’Urso et al., 1991),
which is thought to be a major cause for platelet refractori-
ness (Hod and Schwartz, 2008). The potential clinical
importance of b2M/HLA class I disruption is further sup-
ported by a previous study showing that MKs generated
from b2M knockdown CD34
+ cells could produce HLA-
negative platelets upon injection into immunocompro-
mised mice. Importantly, these HLA-negative platelets
avoided immune detection induced by injection of speciﬁc
anti-HLA antibodies (Gras et al., 2013). With future efforts
aimed at improving the efﬁciency of in vitro platelet gener-
ation from MKs, the application of b2M null iPSCs could
one day provide a replenishable supply of universal plate-
lets for alloreactive patients.
EXPERIMENTAL PROCEDURES
Reagents
STEMspan-ACF and STEMdiff-APEL Media, STEMspan Megakaryo-
cyte Expansion Supplement, mTeSR1, Dispase, and CryoStor CS10
were purchased from STEMCELL Technologies. BMP4 was from
HumanZyme. All other cytokines were obtained from PeproTech.
Y-27632 was purchased from Stemgent. Human Collagen IV
was from Advanced BioMatrix. Matrigel and antibodies for
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Generation of Universal Platelets from Human iPSCsﬂow cytometry were obtained from BD Biosciences. I-BET
151(GSK1210151A) was purchased from ChemieTek. MMP-8 In-
hibitor I (CAS 236403-25-1) was purchased from Millipore. Stem-
Pro Accutase was from Life Technologies. Heparin was purchased
from Sigma.
Human Pluripotent Stem Cell Cultures
The human iPSC line HA1-iPS was reprogrammed by mRNA (War-
ren et al., 2012) and obtained from Allele Biotechnology. The hu-
man iPSC lines 19-9-11T and 6-9-9T (WiCell) were reprogrammed
with episomal vectors. The human iPSC line RHO8 was generated
withretroviralvectorsusingﬁbroblastsderivedfromaRH-Oblood
type donor. The human HDF-iPSC XA line (XA-iPS) was generated
from human dermal foreskin ﬁbroblasts using 6F Reprogramming
Premix (Allele Biotechnology). The hESC lines MA09 and NED07
were derived using single blastomeres (Klimanskaya et al., 2007).
All human pluripotent stem cells were cultured on a Matrigel-
coated surface with mTeSR1 medium. Conﬂuent pluripotent
stem cells were dissociated either with dispase (1 U/ml, STEMCELL
Technologies) or cell dissociation buffer (CDB, Life Technologies).
All pluripotent stem cells used in this study have normal
karyotypes.
Generation of b2M
KO iPSCs
Derivation of b2M
KO iPS was performed by Cellectis Bioresearch
using TALEN technology to disrupt the b2M gene. Brieﬂy, HA-
iPSCs were transfected with a hsb2M TALEN targeting exon 2,
b2M
KO single cells were sorted by FACS, and the TALEN-mediated
deletion in established b2M-negative iPSC clones was validated by
deep sequencing. Lack of b2M expression was conﬁrmed by ﬂow
cytometry. The knockout engineering of HA-iPSCs was performed
under feeder-free and xeno-free culture condition.
MK-and Platelet-Speciﬁc Differentiation
of Pluripotent Stem Cells
Feeder-free iPSCs were dissociated with CDB and resuspended in
fresh mTeSR1 medium containing 10mM of Y27632. Cells were
seeded on human collagen IV-coated plates (5 mg/cm
2) and incu-
bated at 37 Ci n5 %C O 2, 20% O2 for 24 hr. Media were then
changed to STEMspan-ACF + BMP4, vascular endothelial growth
factor, and basic ﬁbroblast growth factor (50 ng/ml each), and cells
were grown for 4 days under hypoxic conditions (5% CO2,5 %O 2)
followed by 2 additional days at 5% CO2, 20% O2. On day 6, cells
were analyzed for cell-surface markers CD31, CD34, CD43, CD144
(VE cadherin), CD105 (Endoglin), CD184 (CXCR4), and CD309
(KDR) by ﬂow cytometry (Accuri C6).
To promote early MKP production, cells were cultured in MK-
SpeciﬁcProgenitorExpansion medium(EXP-M)containing STEM-
diff APEL Medium + thrombopoietin (TPO) (25 ng/ml), stem cell
factor (SCF) (25 ng/ml), Flt-3 ligand (25 ng/ml), interleukin-3
(IL-3) (10 ng/ml), IL-6 (10 ng/ml), and heparin (5 U/ml) for up to
7 days. Nonadherent MKPs were harvested for 4–5 consecutive
days in EXP-M and cryopreserved in CryoStor medium. Samples
of MKPs were checked for CD41a, CD42b, CD31, CD34, CD43,
CD13, CD235a, and CD14 expression by ﬂow cytometry.
To induce MK maturation and platelet formation, MKPs were
cultured in MK maturation medium (MK-M) containing STEM-
Span-ACF + TPO, SCF, IL-6 and IL-9 and heparin (5 U/ml) in ultra-
low attachment plates (Corning). Five micromolar Y-27632 was
added for the ﬁrst 3 days of culture, and cells were incubated in
7% CO2 at 39 C. Cell densities were monitored daily and fresh
medium was added to maintain 10
6 cells/ml for the ﬁrst 4 days.
The maturation of MKs from MKPs was monitored by analyzing
CD41a, CD42b, and CD235a expression. Once proplatelet
morphology (Figure 3A) was observed, platelets were collected
for 3–5 consecutive days and analyzed for CD41a/CD42b
expression.
Toextractplatelets, largeMKswere removedﬁrstusinglow-speed
centrifugation (50 3 g for 10 min), and proplatelets and small MKs
were removed by further 10 min centrifugation at 300 3 g.i P S C
platelets were collected using higher g force (1,000–2,500 3 g)i n
the presence of PGE1 (1 mM). The collected iPSC platelet pellets
were then subjected to further puriﬁcation using a BSA gradient
centrifugation as described previously (Robert et al., 2012).
Human Blood Platelet Preparation and In Vitro
Microscopic Characterizations
Human blood was obtained by venipuncture from healthy volun-
teers, as previously described (Thon et al., 2012). Collections were
performed in accordance with ethics regulation with IRB approval,
and informed consent was provided according to the Declaration
of Helsinki. For electron microscopy, both human blood and
iPSC platelets were ﬁxed and ultrathin sections were stained and
examined with a Tecnai G2 Spirit BioTwin electron microscope
as reported previously (Lu et al., 2011).
Differential interference contrast analysis was performed as
previously reported (Lu etal., 2011). For microtubulecomponents,
samples were stained with an anti-b1-tubulin antibody (Genemed
Synthesis); for actin components, samples were incubated with
Alexa Fluor 568-conjugated phalloidin (Invitrogen). To conﬁrm
cells were anucleate, samples were incubated with Hoechst (Invi-
trogen). For granule localization, samples were incubated with
antibodies against serotonin (EMD Millipore), thrombospondin
4 (Neomarkers), or platelet factor 4 (Peptrotech) and treated with
secondary antibodies, all conjugated to Alexa 488 (Invitrogen).
For contact-activated spreading time lapse, iPSC platelets were
pipetted into chambers formed by mounting a glass coverslip
onto a 10 mm Petri dish with a 1 cm hole. Platelets were permitted
to contact glass by gravity sedimentation, and spreading was
captured at 5 s intervals over a 5 min period.
For size determination, platelets were individually thresholded
from b1-tubulin-labeled samples, and high-content diameter mea-
surements were performed in ImageJ using the linescan and mea-
surementfunctions.Analysiswasconﬁrmedbymanualinspection
of all samples, and improperly thresholded cells were excluded
from the analysis. More than 100 cells were counted for each
condition.
Platelet Kinetics in Live Animals
Macrophages were depleted in NOD/SCID mice (6–7 weeks old,
male) by intravenous injection of liposome-encapsulated clodro-
nateas describedpreviously(HuandYang, 2012). At day 3,human
blood platelets and iPSC platelets were intravenously infused into
macrophage-depleted mice. Blood (30 ml) was collected at different
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analyzed by ﬂow cytometry using allophycocyanin (APC)-conju-
gated anti-human CD41 and Dylight 488-conjugated anti-mouse
CD42c antibodies. The University of Illinois Institutional Animal
Care and Use Committee approved all animal care and experi-
mental procedures.
Real-Time Fluorescence Intravital Microscopy
Intravitalmicroscopyofcremastermusclearterioleswasperformed
as previously described (Lu et al., 2011). NOD/SCID mice were
depleted for macrophages, and the cremaster muscle arteriolar
wall was injured by a micropoint laser. The developing mouse
plateletthrombuswasvisualizedbyinfusionofDylight649-conju-
gated anti-mouse CD42c antibodies (Emfret Analytics, 0.05 mg/g
body weight), and calcein AM-labeled human platelets and iPSC
platelets(3 10
6/mouse)weretheninfusedwithor withoutReoPro
(100 mg) into mice. Fluorescence and bright-ﬁeld images were re-
corded and data were collected for 5 min following vessel wall
injury and analyzed using Slidebook v5.5 (Intelligent Imaging In-
novations). The University of Illinois Institutional Animal Care
and Use Committee approved all animal care and experimental
procedures.
Light Transmission Aggregometry and PAC-1
Activation Assay
HumaniPSC-derivedplateletsorhumanperipheralandcordblood
platelets were counted on a Sysmex Hematoanalyzer XE-2100D,
spun down (15,000 3 g, 15 min), and resuspended in normal hu-
man plasma at the same concentration for light transmission
aggregometry. A total of 25 million platelets suspended in plasma
(270 ml) were placed in Chronolog cuvettes with stir bars at
1,000 rpm. Normal human plasma was used as a blank. The base-
line was set on Aggrolink software, and agonist (30 ml) was added
to a ﬁnal concentration of 20 mM for ADP or 1 U/mL for thrombin
(ﬁnal volume = 300 ml). Data were collected for 10 min, and the
aggregation percentage was calculated with Aggrolink software.
PAC-1 activation assay was performed as previously reported (Lu
et al., 2011).
Expression of b2M and HLA-ABC on HA-iPSCs and
b2M
ko iPSC-Derived MKs and Platelets
Wild-type HA-iPSCs and b2M
ko iPSCs were differentiated into MKs
and platelets using the method described above. Mature MKs from
both lines were stained with ﬂuorescein isothiocyanate (FITC)
anti-human b2M antibody (BioLegend, Clone 2M2) and FITC
anti-human HLA-A,B,C (BioLegend, clone W6/32). FITC-isotype
immunoglobulin Gs were used as control. Platelets generated
from HA-iPSCs and b2M
ko iPSCs were stained with phycoerythrin
anti-human CD42b (BD) and APC anti-human CD41a (BD)
together with either FITC anti-human b2M or FITC anti-human
HLA-A,B,C antibodies. PAC1 activation of platelets was performed
as described previously.
Statistical Analysis
DatawerestatisticallyanalyzedbyStudent’sttestforcomparisonof
twogroups.Differenceswereconsideredsigniﬁcantatp<0.05.‘‘n’’
stands for independent experiments unless otherwise described.
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